Evidence map›Paper›PMID 35145843›Full record

ArticleRespiratory medicine case reports2022

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension.

Mizuki Momoi, Takahiro Hiraide, Yoshiki Shinya, Hiromi Momota, Shogo Fukui, Michiyuki Kawakami, Keiichi Fukuda, Masaharu Kataoka

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Mizuki MomoiDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Takahiro HiraideDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Yoshiki ShinyaDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Hiromi MomotaDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Shogo FukuiDepartment of Rehabilitation, Keio University Hospital, Tokyo, Japan.
Michiyuki KawakamiDepartment of Rehabilitation Medicine, Keio University School of Medicine, Tokyo, Japan.
Keiichi FukudaDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Masaharu KataokaDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Keio University · JPKeio University Hospital · JPUniversity of Occupational and Environmental Health Japan · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effective therapy for pulmonary arterial hypertension (PAH) with inadequate clinical response is scarce except for lung transplantation when prostacyclin infusion is ineffective. The purpose of this study is to investigate the efficacy and safety of selexipag in addition to the infusion of prostacyclin. Nine patients [median 38 (36-49) years of age; 78% female] with PAH whose clinical response was inadequate despite the use of prostacyclin infusion analogs, were evaluated. Addition of selexipag significantly improved hemodynamics and no serious adverse events were observed. Selexipag with prostacyclin infusion analogs can be an effective therapeutic strategy for the PAH patients with inadequate clinical response.

Indexed as

Drug combinationsProstacyclinSelexipag

Identifiers

PMID35145843
PMCPMC8819132
OpenAlexW4210349011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.